Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
ABSI
Valuation N/A
Absci Corp
Price$8.94
Model IV—
P/IV—
Market implies +93.1%/yr
BIAF
Valuation N/A
bioAffinity Technologies, Inc.
Price$5.64
Model IV—
P/IV—
Market implies +59.9%/yr
BIAFW
Valuation N/A
bioAffinity Technologies, Inc.
Price$0.41
Model IV—
P/IV—
Market implies +20.3%/yr
CRL
Deeply overvalued
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Price$298.00
Model IV$114.49
P/IV1.58
Premium +160%
Return to IV: -61.6%
Market implies +17.8%/yr
vs model +5.0% · above model
IBAC
Valuation N/A
IB Acquisition Corp.
Price$10.88
Model IV—
P/IV—
Limited data — see page
ICLR
Deeply undervalued
ICON PLC
Price$164.50
Model IV$399.30
P/IV0.34
Discount 59%
Return to IV: +142.7%
Market implies +5.3%/yr
vs model +23.6% · below model
INCY
Fairly valued
INCYTE CORP
Price$112.75
Model IV$122.44
P/IV1.02
Discount 8%
Return to IV: +8.6%
Market implies +5.8%/yr
vs model +8.6% · in line
IQV
Deeply overvalued
IQVIA HOLDINGS INC.
Price$258.88
Model IV$168.95
P/IV1.08
Premium +53%
Return to IV: -34.7%
Market implies +12.1%/yr
vs model +7.6% · above model
ISPC
Valuation N/A
iSpecimen Inc.
Price$1.09
Model IV—
P/IV—
Market implies +19.6%/yr
vs model +2.0% · above model
MEDP
Undervalued
Medpace Holdings, Inc.
Price$602.70
Model IV$767.78
P/IV0.58
Discount 22%
Return to IV: +27.4%
Market implies +12.9%/yr
vs model +21.2% · below model
MXCT
Valuation N/A
MAXCYTE, INC.
Price$1.02
Model IV—
P/IV—
Market implies +16.6%/yr
NOTV
Valuation N/A
Inotiv, Inc.
Price$0.01
Model IV—
P/IV—
Market implies -50.0%/yr
vs model +50.0% · below model
NRC
Deeply overvalued
NRC HEALTH
Price$20.42
Model IV$7.18
P/IV3.00
Premium +184%
Return to IV: -64.8%
Market implies +16.6%/yr
vs model +3.7% · above model
OABI
Valuation N/A
OmniAb, Inc.
Price$4.66
Model IV—
P/IV—
Market implies +54.9%/yr
vs model +2.0% · above model
OABIW
Valuation N/A
OmniAb, Inc.
Price$0.39
Model IV—
P/IV—
Market implies +21.9%/yr
ONMD
Valuation N/A
OneMedNet Corp
Price$4.82
Model IV—
P/IV—
Market implies +94.7%/yr
ONMDW
Deeply overvalued
OneMedNet Corp
Price$0.03
Model IV$0.01
P/IV3.93
Premium +337%
Return to IV: -77.1%
Market implies +18.8%/yr
vs model +15.0% · above model